News

MimiVax Announces Positive Interim Analysis in Ongoing SurVaxM Clinical Trial -Ongoing clinical trial of SurVaxM in glioblastoma [SURVIVE] has successfully progressed following an interim analysis of trial data -The clinical trial is designed to evaluate the safety, efficacy, and overall benefit of SurVaxM in patients with newly diagnosed glioblastoma who receive standard-of-care treatment combined with SurVaxM -The fully enrolled Phase 2b SURVIVE study will continue as planned […] February 13, 2025

Cordance Medical and EXACT Therapeutics Announce Early Encouraging Data in Brain Cancer Mice Model Cordance Medical, a pioneer in non-invasive medical technologies for brain disease treatment, and EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, are pleased to announce initial positive results indicating more than a doubling (+127-145%) of the uptake of a radiopharmaceutical in brain tumors of mice inoculated with glioblastoma cancer cells, one of the […] January 30, 2025

Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas  –The results from their first-in-human study demonstrated that median overall survival was doubled and progression-free survival improved 3-fold –The Company’s novel sonodynamic therapy platform selectively targets and destroys cancer cells in the brain while preserving healthy tissue  Alpheus Medical, Inc., a private, clinical-stage oncology company pioneering sonodynamic therapy (SDT) for the treatment of solid body […] November 26, 2024

Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy –Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the University of Edinburgh to commercialise its breakthrough Synthetic Super-Enhancer platform, Odysseus, to enable unprecedented precision in targeting aggressive cancers –IQ Capital, Cancer Research Horizons, National Brain Tumor Society, AIN Ventures and Old College Capital now also investors in Trogenix –Dr Ken […] November 18, 2024

Modifi Biosciences Acquired by Merck Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancers  Modifi Biosciences, Inc. (“Modifi Biosciences”), a leader in the development of direct DNA modification enabled cancer therapeutics, today announced that the company has been acquired by Merck, known as MSD outside of the United States and Canada. “In founding Modifi […] October 23, 2024